1 Cheng Y, Liu J, Li Y, et al. Ebola Virus Disease: Virology, pathogenesis, therapy, and vaccines (in Chinese). Chin Sci Bull (Chin Ver), 2014, 59: 2889-2899 [程颖, 刘军, 李昱, 等. 埃博拉病毒病: 病原学、致病机制、治疗与疫苗研究进展. 科学通报, 2014, 59: 2889-
[2]
2 Acharya M. Ebola viral disease outbreak-2014: Implications and pitfalls. Front Public Health, 2014, 2: 263
[3]
3 Miller J E. Public Health Emergency Medical Countermeasures Enterprise and Project BioShield. In: Pilch R F, Zilinskas R A, eds. Encyclopedia of Bioterrorism Defense. New York: John Wiley and Sons, 2005
[4]
4 Trull M C, du Laney T V, Dibner M D. Turning biodefense dollars into products. Nat Biotechnol, 2007, 25: 179-184
[5]
5 Zhong J, Gao W, Huo J P, et al. International comparative study about rare diseases' medicare (in Chinese). Drug Evaluation, 2014, 11: 8-11 [钟军, 郜文, 霍记平, 等. 罕见病医疗保障的国际比较研究. 药品评价, 2014, 11: 8-
[6]
6 Tian M, Tian H, Xie X X, et al. The development of orphan drugs (in Chinese). Drugs & Clinic, 2014, 9: 701-707 [田苗, 田红, 解学星, 等. 罕见病用药现状分析. 现代药物与临床, 2014, 9: 701-
